chemical genomics

(redirected from Chemogenomics)
Also found in: Wikipedia.

chemical genomics

use of organic chemicals, commonly referred to as "small molecules," to study the functions of the cell at the genome level.
Synonym(s): chemogenomics
References in periodicals archive ?
Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.
Rees et al., "Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics," Nature Chemical Biology, vol.
Vert, "Protein-ligand interaction prediction: an improved chemogenomics approach," Bioinformatics, vol.
Lowe et al., "Chemogenomics approaches to rationalizing the mode-of-action of traditional chinese and ayurvedic medicines," Journal of Chemical Information and Modeling, vol.
In our work, a novel in silico pharmacology approach integrated with chemogenomics, polypharmacology and network biology was applied to uncover the therapeutic mechanism of Radix Isatidis from a systematic level.
TDR targets: A chemogenomics resource for neglected diseases.
Their topics include organizing bioactive compound discovery in target gene families, cofactor chemogenomics, chemogenomics with protein secondary-structure mimetics, database systems for knowledge-based discovery, off-target networks derived from ligand set similarity, the chemogenomic analysis of safety profiling data, network and pathway analysis of compound-protein interactions, the flexible pocketome engine for structural chemogenomics, analyzing protein family landscapes with structure-based chemogenomics, and hypothesis-driven screening.
Provider Product Description of Product/approach Iconix.Pharmaceuticals DrugMatrix[TM] Global expression www.iconixpharm.com Chemogenomics profiling in vivo + in vitro > 600 compounds chemogenomic database, +200 validated gene signature sets Gene Logic ToxExpress[TM] ToxExpress[TM] www.genelogic.com reference data base predictive system with In vivo + in vitro models.
A discussion of the patent and two new applications --known as transitional structural chemogenomics and transitional structural chemoproteomics -- was published in the May 2006 issue of Medical Hypotheses (67:1099-1114).
We are very pleased to be working with Elsevier MDL, the market leader in medicinal chemistry knowledge databases, Integration with the Elsevier MDL chemistry space opens up new applications for our products in medicinal chemistry, including high-throughput and high-content screening, hit selection and validation, lead development programs and chemogenomics."
The company's discovery engines integrate cell cycle biology expertise with a large library of gene-based targets, state-of-the-art RNAi functional genomics, chemogenomics and clinical biomarker technologies to rapidly deliver new drugs.